In our study, the frequencies of concurrent EGFR amplification, MET amplification, and PIK3CA mutation in NSCLC patients with METex14 skipping mutation were 6.5, 12.9, and 9.7%, respectively, which are comparable with the findings of the studies by Schrock et al. The gene discussed is MET; the disease is non-small cell lung carcinoma.